Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Decitabine - Janssen-Cilag/Otsuka Pharmaceutical

X
Drug Profile

Decitabine - Janssen-Cilag/Otsuka Pharmaceutical

Alternative Names: 127716; 2'-deoxy-5-azacytidine; 2353-33-5; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; 5-aza-2'-deoxycytidine; DAC; Dacogen; Decitabine mesylate; Deoxycytidine; Dezocitidine; E-7373; NSC-127716

Latest Information Update: 28 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Indiana University; SuperGen
  • Developer Eisai Co Ltd; European Organisation for Research and Treatment of Cancer; Groupe Francophone des Myelodysplasies; HOVON Foundation; Italian Group for Haematological Diseases; Janssen-Cilag; Johnson & Johnson Innovative Medicine; M. D. Anderson Cancer Center; Novartis; Otsuka Pharmaceutical; Sidney Kimmel Cancer Center; Xian-Janssen
  • Class Antineoplastics; Aza compounds; Deoxyribonucleosides; Pyrimidine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
  • Phase III Chronic myelomonocytic leukaemia
  • Phase I/II Malignant melanoma; Ovarian cancer
  • No development reported Myelofibrosis; Solid tumours
  • Discontinued Colorectal cancer

Most Recent Events

  • 28 Nov 2023 No recent reports of development identified for phase-I development in Myelofibrosis(Combination therapy, Treatment-experienced) in Spain (IV)
  • 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
  • 09 Jan 2023 Efficacy data from a phase III trial in Acute myeloid leukaemia presented at the 64th American Society of Hematology Annual Meeting and Exposition(ASH-Hem-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top